Cargando…
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BACKGROUND: Treatment options for oncological diseases have been enhanced by the advent of targeted therapies. The point mutation of the BRAF gene at codon 600 (BRAF V600E) is found in several tumor entities and can be approached with selective inhibitory antibodies. The BRAF inhibitor vemurafenib h...
Autores principales: | Behling, Felix, Barrantes-Freer, Alonso, Skardelly, Marco, Nieser, Maike, Christians, Arne, Stockhammer, Florian, Rohde, Veit, Tatagiba, Marcos, Hartmann, Christian, Stadelmann, Christine, Schittenhelm, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924254/ https://www.ncbi.nlm.nih.gov/pubmed/27350555 http://dx.doi.org/10.1186/s13000-016-0506-2 |
Ejemplares similares
-
The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019) -
Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma
por: Behling, Felix, et al.
Publicado: (2020) -
Oncogenic BRAF Alterations and Their Role in Brain Tumors
por: Behling, Felix, et al.
Publicado: (2019) -
High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma
por: Behling, Felix, et al.
Publicado: (2018) -
Successes and challenges in modeling heterogeneous BRAF(V600E) mutated central nervous system neoplasms
por: Xing, Yao Lulu, et al.
Publicado: (2023)